Characterization of Proliferating Compartment in B-Cell Patients and in Healthy Aging Subjects
Study Details
Study Description
Brief Summary
By ingesting a non-radioactive and non-toxic compound "heavy water" for 6 weeks, the DNA of newly developed cells in the body of subjects with B-cell chronic lymphocytic leukemia can be labeled and followed by performing routine blood draws at specified time intervals. By using mass spectrometric analysis we can measure how quickly new B-CLL cells are generated in the bone marrow and how quickly they leave the blood, a measure of cell turnover. This will help us to better understand the unique characteristics of this disease process.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
By ingesting a non-radioactive and non-toxic compound "heavy water" for 6 weeks, the DNA of newly developed cells in the body of subjects with B-cell chronic lymphocytic leukemia (B-CLL) can be labeled and followed by performing routine blood draws at specified time intervals. By using mass spectrometric analysis we can measure how quickly new B-CLL cells are generated in the bone marrow and how quickly they leave the blood, a measure of cell turnover. This will help us to better understand the unique characteristics of this disease process.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Chronic Lymphocytic Leukemia Chronic Lymphocytic Leukemia |
Outcome Measures
Primary Outcome Measures
- Characterization of the Proliferating Compartment in B-CLL Patients and in Healthy Aging Subjects [1 year]
B-CLL is a dx of accumulation rather than proliferation. Evidence for various forms of clonal evolution suggests that B-CLL clones may be more dynamic than previously assumed. A non-radioactive, stable isotopic labeling method to measure B-CLL cell kinetics in vivo. Subjects drank an aliquot of 2H2O daily for 84 days, and 2H incorporation into the deoxyribose moiety of DNA of their newly divided B-CLL cells, measured by gc/ms, during the labeling period. Birth rates were calculated from the kinetic profiles. Death rates were defined as the difference between calculated birth and growth rates.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
18 years of age,
-
Patients must be willing to contribute the required amount of blood without compromising their well being,
-
Participants must be willing to be contacted in the future.
Exclusion Criteria:
-
Pregnancy,
-
Patients who are known to be anemic, with a hemoglobin < 8,
-
Patients who are known to be infected with HIV.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Feinstein Institute for Medical Research | Manhasset | New York | United States | 11030 |
Sponsors and Collaborators
- Northwell Health
Investigators
- Principal Investigator: Nicholas Chiorazzi, MD, Feinstein Institute for Medical Research
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 05-05-096
- GAC # 0117